Canaccord Genuity reiterated a 'Buy' rating on HIMS, along with a $32 price target, implying a 16% upside from current levels. ・The brokerage sees peptides as a potential long-term growth driver as ...

The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer. More than one in three people will develop cancer in their lifetime2 ...

The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers ...

Hims and Hers Health has acquired at-home lab testing facility Trybe Labs. The company separately announced it has acquired a U.S.-based peptide facility in California. The startup is expanding its ...

Hims & Hers, a leading telehealth platform, announced today that it plans to introduce at-home testing for its customers after acquiring a new lab. The company acquired Trybe Labs, an at-home testing ...

Hims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab testing. Positive analyst coverage may also be boosting the stock. Here’s ...

The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer The company will offer access to Galleri®, an innovative blood test ...

The deal will allow the telehealth company to offer at-home blood draws and more comprehensive pretreatment testing to its users. "Access to richer data allows us to deepen the insights that providers ...